https://substackcdn.com/image/fetch/$s_!kTwS!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F598dcbe6-902d-445d-9926-802aff128108_1254x1254.png The FDA’s own briefing document reveals that 75.3% of senior mRNA-vaccine recipients experienced at least one solicited adverse reaction within seven days, compared with 49.3% of those receiving Fluzone High-Dose. Even more concerning, severe (Grade 3) systemic reactions occurred in 6.7% of mRNA recipients versus 1.7% with the traditional high-dose flu vaccine—nearly four times as frequently. Even worse, the pivotal efficacy trial contained no placebo group. Instead, Moderna compared mFLUSIVA against traditional flu vaccines. A novel mRNA injection produced adverse reactions in three out of four recipients, induced severe systemic reactions nearly four times as often as the traditional high-dose vaccine, lacked a placebo-controlled pivotal efficacy trial, and the FDA approved it anyway. Our regulatory agencies remain CAPTURED. Source: https://www.thefocalpoints.com/p/fda-approves-modernas-first-ever